Skip to main content
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Menu
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology

Experts Urge Shift to CBT-I Over Sleep Meds for Chronic Insomnia

November 20, 2026 Health Desk Health

Cognitive-behavioral therapy for insomnia (CBT-I) provides a safer and more effective alternative to sedative medications for patients with chronic sleep difficulties, according to presentations delivered at the Family Medicine Forum (FMF) 2026.

As clinical standards shift, experts are advocating for a transition away from long-term pharmaceutical reliance.

Key Clinical Takeaways:

  • Chronic insomnia is defined as sleep difficulty occurring at least three nights per week for three months or longer.
  • CBT-I, a structured 4- to 8-week program, addresses underlying cognitive and behavioral patterns rather than masking symptoms.
  • Pharmaceutical sleep aids carry significant risks for older adults, including increased susceptibility to falls, fractures, and cognitive impairment.

Transitioning from Pharmacological Management

Doctors are shifting chronic insomnia treatment away from sedative prescriptions toward non-drug approaches. David Gardner, PharmD, a professor of psychiatry at Dalhousie University, emphasized the necessity of this shift during the FMF 2026 proceedings. “Now is the time for us to be all together on this, to be a part of the transformation of insomnia management from pharmacologic to nonpharmacologic approaches,” Gardner told Medscape News Canada.

While basic sleep hygiene—such as maintaining a dark environment and avoiding electronic devices before bed—remains common advice, these measures often fail to resolve chronic cases. Gardner said clinicians must separate short-term sleep complaints from chronic insomnia, which needs stronger treatment. Standard practice now favors CBT-I, an evidence-based framework that helps patients modify thought patterns and habits that actively interfere with restorative sleep.

Risks of Long-Term Sedative Use

The reliance on pharmaceutical sleep aids presents a growing concern, particularly as patients age. Gardner highlighted that the vulnerability to adverse drug effects is most pronounced in older, frailer populations. Common risks associated with these agents include increased rates of falls, fractures, and cognitive impairment. Research also suggests a link between these medications and a higher incidence of flu-related pneumonia, stemming from the drugs’ suppressive effects on the immune system.

Pharmacological options often provide only marginal gains. Stephanie Lynch, PharmD, a research lead at Queen’s University, pointed to studies comparing the benzodiazepine temazepam with placebo. Polysomnography data indicated that the medication reduced sleep initiation time by only 11 minutes, while self-assessments showed a reduction of 7 minutes.

The drug was associated with 21 additional minutes of total sleep, a benefit that many clinicians view as insufficient when weighed against the potential for side effects and long-term dependency.

Implementing Deprescribing Strategies

Clinicians are increasingly encouraged to adopt deprescribing protocols for patients currently using sleep aids. Lynch suggested that providers initiate conversations regarding why a patient continues to take the medication, whether they perceive it as effective, and if they are experiencing related side effects.

Documenting sleep timing, daytime naps, and the use of alcohol or other substances in a sleep diary can provide the necessary data to facilitate these discussions and safely reduce dosage.

For patients with severe insomnia, CBT-I should serve as the default standard of care, according to Guylène Thériault, MD, a family physician practicing in Gatineau, Quebec.

Thériault said that the number needed to treat with CBT-I is three, a figure she described as superior to pharmaceutical alternatives. “I have to offer CBT-I to three patients for one of them to have success, which is huge,” Thériault told Medscape News Canada.

Expanding Access to Evidence-Based Programs

While CBT-I was historically limited to in-person sessions with trained therapists, digital accessibility is expanding. Programs such as the nonprofit Sleepwell, which receives funding from the Drug Evaluation Alliance of Nova Scotia and the government of Nova Scotia, serve as a resource for identifying self-guided apps and structured programs.

Other resources, including the Canadian Medication Appropriateness and Deprescribing Network and Choosing Wisely Canada, provide clinicians with patient handouts and established deprescribing schedules.

Transitioning patients who have been on benzodiazepines for extended periods remains a clinical challenge. Thériault acknowledged that replacing long-term medication with CBT-I requires careful management, but emphasized that it remains a necessary conversation.

As the medical community continues to refine these protocols, patients seeking to address persistent sleep disturbances are encouraged to consult with a primary care physician or a sleep medicine specialist to develop a personalized, non-pharmacological care plan.

David Gardner, PharmD, a professor of psychiatry at Dalhousie University in Halifax, Nova Scotia, co-developed the Sleepwell knowledge mobilization program and the Bloom Program, a province-wide community pharmacy service for mental illness and addictions.

He also serves as an executive member of the Canadian Medication Appropriateness and Deprescribing Network and is a member of the Canadian Sleep Research Consortium. Gardner trained in pharmacy at the University of Toronto, earned an MSc in Community Health and Epidemiology at Dalhousie University, and completed a PharmD at the University of British Columbia.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.

More on this story: Long Sleep Tied to 51% Higher Mortality Risk in Adults With Heart Disease · Researchers Say Sleep Loss Impairs Executive Decision-Making

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related reading

  • Former US Ambassador to Bulgaria Eric Rubin Dies
  • CSL Behring Invests €610 Million to Expand Marburg Plasma Plant, Adding 100 Jobs

Related

Search:

World Today News

World Today News is your trusted source for global journalism — breaking headlines, in-depth analysis, and reporting from around the world.

Quick Links

  • Privacy Policy
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Disclaimer
  • DMCA Policy
  • Do not sell my info
  • EDITORIAL TEAM
  • Terms & Conditions

Browse by Location

  • GB
  • NZ
  • US

Connect With Us

© 2026 World Today News. All rights reserved. Your trusted global news source directory.
For contact, advertising, copyright, issues email: [email protected]

Privacy Policy Terms of Service